Supplementary Table 1. Baseline characteristics of active TB vs. LTBI groups in the primary analysis population

| Characteristic                                      | Total (n = 542) | LTBI group (n = 532) | Active TB group (n = 10) | p value |
|-----------------------------------------------------|-----------------|----------------------|--------------------------|---------|
| Initial CT vs. CXR                                  | 320 (59)        | 312 (58.6)           | 8 (80)                   | 0.174   |
| Age, yr                                             | 46.9 ± 11.5     | 47.0 ± 11.5          | 45.0 ± 13.8              | 0.476   |
| Female sex                                          | 398 (73.4)      | 392 (73.7)           | 6 (60)                   | 0.332   |
| Body mass index, kg/m²                               | 23.6 ± 3.6      | 23.6 ± 3.6           | 22.1 ± 1.7               | 0.418   |
| Occupation                                          |                 |                      |                          | 0.394   |
| Hospital                                            | 246 (45.4)      | 240 (45.1)           | 6 (60)                   |         |
| Kindergarten                                        | 138 (25.5)      | 136 (25.6)           | 2 (20)                   |         |
| Nursing facility                                    | 47 (8.7)        | 47 (8.8)             | 0                        |         |
| School                                              | 9 (1.7)         | 9 (1.7)              | 0                        |         |
| Postnatal care center                               | 6 (1.1)         | 6 (1.1)              | 0                        |         |
| Military personnel                                  | 1 (0.2)         | 1 (0.2)              | 0                        |         |
| Others                                              | 95 (17.5)       | 93 (17.5)            | 2 (20)                   |         |
| Charlson comorbidity index                          | 0.2 ± 0.7       | 0.2 ± 0.7            | 0.2 ± 0.6                | 0.838   |
| High risk of active TB                              | 74 (13.7)       | 73 (13.7)            | 1 (10)                   | 0.594   |
| Radiologically healed TB                            | 43 (7.9)        | 43 (8.1)             | 0                        | 0.349   |
| Transplantation recipient or candidate              | 18 (3.3)        | 17 (3.2)             | 1 (10)                   | 0.235   |
| TNF blocker user or candidate                       | 17 (3.1)        | 17 (3.2)             | 0                        | 0.566   |
| HIV infection                                       | 1 (0.2)         | 1 (0.2)              | 0                        | 0.891   |
| Moderate risk of active TB                          | 40 (7.4)        | 39 (7.3)             | 1 (10)                   | 0.539   |
| Diabetes mellitus                                   | 23 (4.3)        | 23 (4.3)             | 0                        | 0.502   |
| End-stage renal disease                             | 18 (3.3)        | 17 (3.2)             | 1 (10)                   | 0.235   |
| Steroid maintenance treatment                       | 3 (0.6)         | 3 (0.6)              | 0                        | 0.812   |
| History of gastrectomy                              | 1 (0.2)         | 1 (0.2)              | 0                        | 0.891   |
| Symptoms                                            | 13 (2.4)        | 13 (2.4)             | 0                        | 0.617   |
| Cough                                               | 8 (1.5)         | 8 (1.5)              | 0                        | 0.696   |
| Sputum                                              | 10 (1.8)        | 10 (1.9)             | 0                        | 0.662   |
| Fatigue                                             | 1 (0.2)         | 1 (0.2)              | 0                        | 0.891   |
| Diagnostic method for TB infection                  |                 |                      |                          | 0.891   |
| IGRA                                                | 541 (99.8)      | 531 (99.8)           | 10 (100)                 |         |
| Tuberculin skin test                                | 1 (0.2)         | 1 (0.2)              | 0                        |         |
| Suspected as active TB in initial imaging           | 21 (3.9)        | 11 (2.1)             | 10 (100)                 | < 0.001 |
| Initial radiologic abnormalities                     | 208 (38.4)      | 198 (37.2)           | 10 (100)                 | < 0.001 |
| Calcified granulomas or lymph nodes                  | 161 (29.7)      | 161 (30.3)           | 0                        | 0.038   |
| Fibronodular scarring                               | 42 (7.7)        | 41 (7.7)             | 1 (10)                   | 0.788   |
| Pleural thickening or calcification                 | 6 (1.1)         | 6 (1.1)              | 0                        | 0.736   |
| Cavitation                                          | 1 (0.2)         | 1 (0.2)              | 0                        | 0.891   |
| Consolidation                                       | 2 (0.4)         | 0                    | 2 (20)                   | < 0.001 |
| Centrilobular and tree-in-bud nodules               | 32 (5.9)        | 22 (4.1)             | 10 (100)                 | < 0.001 |

Values are presented as number (%) or mean ± standard deviation.

TB, tuberculosis; LTBI, latent tuberculosis infection; CT, computed tomography; CXR, chest X-ray; TNF, tumor necrosis factor; HIV, human immunodeficiency virus; IGRA, interferon gamma release assay.